3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Stomach Neoplasms
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Neuroblastoma
1
Neoplasm Metastasis
1
Glioblastoma
1
Drug-Related Side Effects and Adverse Reactions
1
Depression
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Anxiety Disorders
1
All Solid Tumors
1
Interventions
Cisplatin
3
Amifostine
3
Radiotherapy
2
Paclitaxel
2
sodium thiosulfate
1
selinexor
1
Trastuzumab
1
Topotecan
1
Pharmaceutical Preparations
1
Nivolumab
1
Methotrexate
1
Imatinib Mesylate
1
Filgrastim
1
Etoposide
1
Drug Combinations
1
Doxorubicin
1
Docetaxel
1
Cyclophosphamide
1
Chemotherapy, Adjuvant
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Drug-Related Side Effects and Adverse Reactions
×
Pharmaceutical Preparations
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled